Particle size reduction is one of the most effective and widely applied strategies for enhancing the bioavailability of poorly soluble active pharmaceutical ingredient (API) substances. When the oral bioavailability of a drug is limited by dissolution rate rather than by intestinal permeability, reducing the median particle diameter from hundreds of micrometers to the 1–10 µm range can accelerate dissolution sufficiently to achieve therapeutic plasma levels. Laboratory-scale milling is the primary tool for exploring and establishing particle size reduction strategies during formulation development, and the decisions made at this stage directly shape downstream manufacturing specifications and regulatory filings under frameworks such as the International Council for Harmonisation (ICH) Q6A guideline.
How particle size governs dissolution rate and oral bioavailability
Dissolution rate — not equilibrium solubility — is the biopharmaceutical parameter most directly influenced by particle size reduction. The Noyes-Whitney equation, first described in 1897, quantifies this relationship: dissolution rate is proportional to the surface area of the dissolving solid, the diffusion coefficient of the drug in solution, and the concentration gradient between the particle surface and the bulk fluid. Reducing particle size increases total surface area relative to mass — scaling inversely with particle diameter — which accelerates the rate at which drug molecules transfer into solution in the gastrointestinal (GI) tract.
It is important to distinguish dissolution rate from equilibrium solubility. Micronization — reducing API particles to the 1–10 µm range — increases the dissolution rate of a drug without meaningfully changing its equilibrium solubility. This distinction matters clinically: faster dissolution accelerates absorption, but the total amount that can dissolve in a given volume of GI fluid is unchanged.
Nanosizing, which reduces particles below 1 µm, can additionally increase apparent equilibrium solubility through the Ostwald-Freundlich effect, but requires different equipment and formulation strategies. For most laboratory development workflows targeting oral solid dosage forms, micronization by ball or jet milling is the primary approach.
Drugs that dissolve slowly in GI fluids risk missing their absorption window — the segment of the small intestine where the drug must be in solution to be absorbed. Particle size reduction mitigates this risk for dissolution-rate-limited compounds by ensuring sufficient drug is in solution within the residence time available.
Lab Quality Management Certificate
The Lab Quality Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Which APIs benefit most from particle size reduction: the BCS framework
The Biopharmaceutics Classification System (BCS), incorporated into regulatory guidance by the FDA and ICH, classifies APIs according to their solubility and permeability and provides a framework for predicting which compounds will benefit from particle size reduction.
BCS Class II APIs — low solubility, high permeability — gain the greatest bioavailability benefit from particle size reduction. Dissolution is the rate-limiting step for absorption in these compounds, so any increase in dissolution rate directly translates to higher and more consistent bioavailability. A large proportion of new chemical entities (NCEs) in pharmaceutical pipelines fall into Class II, making micronization a routine development activity for new drug substances.
BCS Class IV APIs — low solubility, low permeability — present a more complex picture. Particle size reduction can improve dissolution rate but does not address the permeability barrier; bioavailability enhancement from milling alone is therefore limited and must be evaluated alongside permeability-enhancing strategies.
BCS Class I APIs — high solubility, high permeability — are generally not candidates for particle size reduction because dissolution is rapid regardless of particle diameter. BCS Class III APIs are limited by permeability rather than dissolution, and milling similarly offers limited benefit. Understanding BCS classification before initiating milling development prevents wasted effort on APIs that will not respond to size reduction.
| BCS class | Solubility | Permeability | Benefit from particle size reduction |
|---|---|---|---|
| Class I | High | High | Minimal — dissolution not rate-limiting |
| Class II | Low | High | High — dissolution rate-limited; primary candidate |
| Class III | High | Low | Limited — permeability is rate-limiting step |
| Class IV | Low | Low | Partial — dissolves faster but permeability limits absorption |
Lab milling methods for API particle size reduction
Several mill types are used at laboratory scale for API particle size reduction, each with distinct advantages in terms of achievable particle size, heat generation, contamination risk, and throughput.
Interested in lab tools and techniques?
Ball and planetary mills are versatile instruments for both dry and wet API milling. Dry ball milling of pharmaceutical powders typically achieves D90 values in the 10–50 µm range depending on API hardness and milling duration. For wet ball milling — dispersing the API in a liquid vehicle and milling with high-density beads — median particle sizes below 1 µm (nanosizing) are achievable, producing nanosuspensions suitable for oral or injectable formulations.
Media selection for pharmaceutical applications should prioritize zirconia or high-purity alumina to minimize elemental contamination; contamination risks associated with different grinding media materials are discussed in Lab Manager's grinding media selection guide.
Jet mills use high-velocity streams of compressed gas to accelerate particles into collision with each other, achieving micronization to 1–5 µm with no moving contact parts. This eliminates the contamination risk associated with grinding media wear and avoids the frictional heat generated by mechanical mills. Jet milling is the most common production-scale micronization technology in pharmaceutical manufacturing, and laboratory-scale air jet mills allow D50 targets of approximately 1–3 µm to be investigated in batches of one gram or less, making them suitable for early development with limited API quantities.
Cryogenic mills cool the sample and grinding chamber with liquid nitrogen before and during milling, maintaining temperatures well below the glass transition temperature (Tg) of the API. Cryogenic milling is the method of choice for three categories of pharmaceutical materials: thermolabile APIs that degrade or melt during conventional milling; waxy or gummy compounds that resist comminution at ambient temperature; and APIs where amorphous content must be controlled, because milling below the Tg suppresses heat-induced amorphization while still achieving particle size reduction.
- Ball mills (dry): general API size reduction, D90 10–50 µm; low cost, risk of crystallinity change at ambient temperature
- Planetary mills (wet): nanosuspension production, D50 < 1 µm; media contamination risk requires careful selection
- Jet mills: micronization 1–5 µm; no media contamination; preferred for inhaled and injectable APIs
- Cryogenic mills: thermolabile or waxy APIs; suppresses amorphization; lab-scale batches typically range from sub-gram to tens of grams
- Pin/rotor mills: coarse size reduction to 50–200 µm; high throughput; limited to non-heat-sensitive compounds
Solid-state risks: polymorphism, amorphization, and crystallinity changes
Mechanical energy introduced during milling can alter the solid-state form of an API, with potentially significant consequences for solubility, stability, and regulatory compliance. Milling-induced amorphization occurs when the lattice energy of the crystalline material is overcome by the mechanical stress of grinding, converting ordered crystalline domains to disordered amorphous regions. Amorphous API typically exhibits higher apparent solubility and faster dissolution than its crystalline form, which can be advantageous — but the amorphous state is thermodynamically unstable and may recrystallize during storage, altering bioavailability unpredictably over the product shelf life.
Polymorphic conversion — where milling drives a transition between crystalline forms of the same compound — is a related concern. Different polymorphs of an API can have substantially different solubility profiles; if milling changes the polymorph, the dissolution performance of the milled product may not reflect the drug substance specification. Solid-state characterization of milled API by X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) is standard practice before and after milling to confirm that crystalline form is preserved.
Cryogenic milling significantly reduces amorphization risk by conducting size reduction below the Tg of the API. For compounds where some amorphization is acceptable or desirable, controlled milling conditions and excipient co-milling can stabilize the amorphous form by preventing molecular mobility and subsequent recrystallization.
Regulatory requirements: ICH Q6A and particle size specifications
ICH Q6A (Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, 1999) identifies particle size as a potentially critical quality attribute for drug substances where it affects bioavailability, dissolution, or formulation manufacturability. Decision Tree #3 within Q6A provides a structured framework for determining whether a particle size specification is required for a given API: if bioavailability is affected, or if the drug substance is used in a suspension or for inhaled delivery, a particle size specification is mandated.
For an API requiring particle size control, the specification must include both a central tendency measure (typically D50) and a distribution measure (D90, and sometimes D10) to capture the breadth of the particle size distribution, not just its midpoint. A narrow particle size distribution produces more consistent dissolution behavior than a wide distribution at the same median size, because the coarse tail of a wide distribution can disproportionately slow dissolution kinetics.
Establishing a particle size specification during development requires:
- Demonstrating a relationship between particle size and dissolution or bioavailability performance in a clinically relevant in vitro or in vivo model
- Defining the acceptable particle size range that ensures equivalent biopharmaceutical performance across batches
- Validating the particle size measurement method (typically laser diffraction) for specificity, repeatability, and intermediate precision
- Documenting the milling process parameters sufficient to reproducibly achieve the target distribution
Lab Manager's guide to pharmaceutical particle size analysis covers the measurement and regulatory dimensions of particle size in depth, while the full context of mill selection for pharmaceutical sample preparation is addressed in Lab Manager's complete guide to lab mills and grinders.
Conclusion: particle size reduction as a bioavailability strategy requires solid-state discipline
Particle size reduction of APIs is a powerful and well-established bioavailability enhancement strategy for BCS Class II compounds, but API particle size reduction requires more than selecting a mill and setting a target particle size. Solid-state integrity must be verified before and after milling, the downstream analytical method must be capable of detecting any crystallinity or polymorphism changes, and the resulting particle size specification must be set within an ICH Q6A-compliant framework that links milling parameters to biopharmaceutical performance. Laboratories that treat particle size reduction as a purely mechanical operation risk producing milled API that meets a size target while failing its solid-state and dissolution requirements.
References
- International Council for Harmonisation. ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Geneva: ICH, 1999. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
- Csicsák, D. et al. "The effect of the particle size reduction on the biorelevant solubility and dissolution of poorly soluble drugs with different acid-base character." Pharmaceutics, 2023, 15(1), 278. https://doi.org/10.3390/pharmaceutics15010278
- Martínez, L.M. et al. "Mechanical activation by ball milling as a strategy to prepare highly soluble pharmaceutical formulations in the form of co-amorphous, co-crystals, or polymorphs." Pharmaceutics, 2022, 14(10), 2003. https://doi.org/10.3390/pharmaceutics14102003
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
